Understanding GLP-1 Pricing and Rebate Structures

Understanding GLP-1 Pricing and Rebate Structures

GLP-1 medications like Ozempic®, Wegovy®, and Zepbound® are now one of the fastest-growing drug spend categories for employers. Most people know that they’re expensive.

What many employers don’t know is something more basic: What they’re actually paying.

Not the list price, not the “rebate guarantee,” but the true net cost.

Why GLP-1 Pricing Is So Hard to Understand

With most purchases, you pay a price, and you get a product. However, drug pricing and PBMs don’t operate within that system.

Instead, PBM pricing is fragmented and bundled. The model is closer to buying a car by negotiating the price of every single part separately, rather than being told the final total later.

In practice, that means:

  • A list price (AWP or WAC)
  • Multiple rebates negotiated after the fact
  • Administrative and dispensing fees layered in
  • Contracts that bundle GLP-1s together with dozens of other drugs

With this bundled rebate structure, there’s no single, obvious number that represents an employer's net GLP-1 cost.

How Rebates Add Confusion 

Rebates are often positioned as savings, but they also hide what’s happening with drug pricing.

Here’s why:

  • Rebates are typically paid months later
  • They may be guaranteed, estimated, or volume-dependent
  • They can be bundled across an entire drug portfolio, not just GLP-1s
  • Employers often see a single rebate line item, not drug-level detail

A plan sponsor might hear: “You’re getting 40–50% off.” What’s harder to answer is:

  • 40–50% off what?
  • Which medications, which brands? 
  • Net of which fees?
  • Passed through in full, or partially retained?

Even sophisticated employers often don’t have clean answers to those questions.

The Bundling Effect Most Employers Miss

PBMs don’t just negotiate GLP-1 prices and rebates in isolation. They bundle brand-name drugs, generics, market-share commitments, and volume guarantees.

This bundling makes it difficult to evaluate GLP-1 costs on their own, because there isn’t a clear net cost for GLP-1 medications up front. 

When these medications and other rules are bundled together, it makes it challenging to understand what the price of each medication is on its own. That leaves many decision-makers waiting for a rebate check, hoping it matches the budget. 

Start With the Right Questions

PBMs and consultants have access to data: 

  • Drug-level claims data
  • Gross vs. net cost detail
  • Rebate structures
  • Contract terms that explain how pricing works

If data isn’t easily accessible, what might be missing is the right questions.

Questions like:

  • What is our net GLP-1 cost after rebates?
  • Are rebates fully passed through?
  • Which GLP-1s drive the highest spend?
  • How are price changes handled mid-contract?

GLP-1 pricing and rebate structures are complex by design. Understanding how PBMs bundle pricing, rebates, and contracts is the first step toward clarity.

Employers who want to truly understand their spend can focus on this intersection of GLP-1 medications, PBM economics, and rebate structures, starting with what data exists and which questions matter most.